Shopping Cart 0
Cart Subtotal
AED 0

Synairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 1376

Details

Synairgen Plc (SNG)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-/SNG001) for chronic obstructive pulmonary disease (COPD) in Phase II trial; The company develops drugs based on BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc Key Recent Developments

Sep 30,2019: Synairgen: Interim results for the six months ended 30 June 2019

Apr 18,2019: Synairgen: Directorate change, posting of annual report, and notice of AGM

Feb 25,2019: Synairgen: Preliminary statement of results for the year ended 31 December 2018

Jan 17,2019: Synairgen announces positive progress on LOXL2 programme by Pharmaxis

Sep 25,2018: Synairgen: Interim results for the six months ended 30 June 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Synairgen Plc-Key Facts

Synairgen Plc-Key Employees

Synairgen Plc-Key Employee Biographies

Synairgen Plc-Major Products and Services

Synairgen Plc-History

Synairgen Plc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Synairgen Plc-Business Description

R&D Overview

Synairgen Plc-SWOT Analysis

SWOT Analysis-Overview

Synairgen Plc-Strengths

Synairgen Plc-Weaknesses

Synairgen Plc-Opportunities

Synairgen Plc-Threats

Synairgen Plc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Synairgen Plc, Recent Deals Summary

Section 5-Company's Recent Developments

Sep 30, 2019: Synairgen: Interim results for the six months ended 30 June 2019

Apr 18, 2019: Synairgen: Directorate change, posting of annual report, and notice of AGM

Feb 25, 2019: Synairgen: Preliminary statement of results for the year ended 31 December 2018

Jan 17, 2019: Synairgen announces positive progress on LOXL2 programme by Pharmaxis

Sep 25, 2018: Synairgen: Interim results for the six months ended 30 June 2018

Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Synairgen Plc, Performance Chart (2014-2018)

Synairgen Plc, Ratio Charts

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Synairgen Plc, Key Facts

Synairgen Plc, Key Employees

Synairgen Plc, Key Employee Biographies

Synairgen Plc, Major Products and Services

Synairgen Plc, History

Synairgen Plc, Subsidiaries

Synairgen Plc, Key Competitors

Synairgen Plc, Ratios based on current share price

Synairgen Plc, Annual Ratios

Synairgen Plc, Annual Ratios (Cont...1)

Synairgen Plc, Interim Ratios

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Synairgen Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Synairgen Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Verona Pharma Plc

Theravance Biopharma Inc

Oxagen Ltd

Novartis AG

Napp Pharmaceuticals Ltd

GlaxoSmithKline Plc

Company Profile

Company Profile Title

Synairgen Plc (SNG)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-/SNG001) for chronic obstructive pulmonary disease (COPD) in Phase II trial; The company develops drugs based on BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc Key Recent Developments

Sep 30,2019: Synairgen: Interim results for the six months ended 30 June 2019

Apr 18,2019: Synairgen: Directorate change, posting of annual report, and notice of AGM

Feb 25,2019: Synairgen: Preliminary statement of results for the year ended 31 December 2018

Jan 17,2019: Synairgen announces positive progress on LOXL2 programme by Pharmaxis

Sep 25,2018: Synairgen: Interim results for the six months ended 30 June 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Synairgen Plc-Key Facts

Synairgen Plc-Key Employees

Synairgen Plc-Key Employee Biographies

Synairgen Plc-Major Products and Services

Synairgen Plc-History

Synairgen Plc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Synairgen Plc-Business Description

R&D Overview

Synairgen Plc-SWOT Analysis

SWOT Analysis-Overview

Synairgen Plc-Strengths

Synairgen Plc-Weaknesses

Synairgen Plc-Opportunities

Synairgen Plc-Threats

Synairgen Plc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Synairgen Plc, Recent Deals Summary

Section 5-Company's Recent Developments

Sep 30, 2019: Synairgen: Interim results for the six months ended 30 June 2019

Apr 18, 2019: Synairgen: Directorate change, posting of annual report, and notice of AGM

Feb 25, 2019: Synairgen: Preliminary statement of results for the year ended 31 December 2018

Jan 17, 2019: Synairgen announces positive progress on LOXL2 programme by Pharmaxis

Sep 25, 2018: Synairgen: Interim results for the six months ended 30 June 2018

Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Synairgen Plc, Performance Chart (2014-2018)

Synairgen Plc, Ratio Charts

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Synairgen Plc, Key Facts

Synairgen Plc, Key Employees

Synairgen Plc, Key Employee Biographies

Synairgen Plc, Major Products and Services

Synairgen Plc, History

Synairgen Plc, Subsidiaries

Synairgen Plc, Key Competitors

Synairgen Plc, Ratios based on current share price

Synairgen Plc, Annual Ratios

Synairgen Plc, Annual Ratios (Cont...1)

Synairgen Plc, Interim Ratios

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Synairgen Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Synairgen Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Verona Pharma Plc

Theravance Biopharma Inc

Oxagen Ltd

Novartis AG

Napp Pharmaceuticals Ltd

GlaxoSmithKline Plc